Open AccessSafety and efficacy of netupitant/palonosetron and dexamethasone in classical Hodgkin’s lymphoma patients with inadequate chemotherapy-induced nausea and vomiting prophylaxis with palonosetron and dexamethasone: a single-center real-life experience
Author(s) -
Vittorio Ruggero Zilioli,
Cristina Muzi,
Periana Minga,
Paolo Codega,
Lara Crucitti,
Erika Meli,
Anna Esposito,
Claudia Panico,
Chiara Rusconi,
Roberto Cairoli
Publication year - 2020
Publication title -
international journal of hematologic oncology
Language(s) - English
Resource type - Journals
eISSN - 2045-1407
pISSN - 2045-1393
DOI - 10.2217/ijh-2020-0001
Subject(s) - palonosetron , medicine , chemotherapy induced nausea and vomiting , dacarbazine , abvd , adverse effect , nausea , vomiting , vinblastine , antiemetic , procarbazine , anesthesia , chemotherapy , oncology , vincristine , cyclophosphamide
We analyzed safety of NEPA (netupitant/palonosetron) and dexamethasone (NEPA+DEX) for the management of chemotherapy-induced nausea and vomiting (CINV) in classical Hodgkin’s lymphoma patients that experienced CINV with a prophylaxis with palonosetron (PALO + DEX). In a retrospective, monocentric, noncomparative study, we analyzed adverse events and CINV grading in patients who switched from PALO + DEX to NEPA + DEX. Among 32 patients treated with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) during the study period, 47% did not properly control CINV with PALO + DEX and were shifted to NEPA + DEX. Among these, 53.3% properly controlled CINV is for all the remaining chemotherapy cycles. We did not observe an increase of adverse events after switching to NEPA. In our study, NEPA did not show drug–drug interaction with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy agents and NEPA administration was well tolerated with mild and transient adverse events.